201 related articles for article (PubMed ID: 33594045)
1. Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis.
Palladini G; Paiva B; Wechalekar A; Massa M; Milani P; Lasa M; Ravichandran S; Krsnik I; Basset M; Burgos L; Nuvolone M; Lecumberri R; Foli A; Puig N; Sesta MA; Bozzola M; Cascino P; Nevone A; Ripepi J; Berti P; Casarini S; Annibali O; Orfao A; San-Miguel J; Merlini G
Blood Cancer J; 2021 Feb; 11(2):34. PubMed ID: 33594045
[TBL] [Abstract][Full Text] [Related]
2. Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis.
Sidana S; Muchtar E; Sidiqi MH; Jevremovic D; Dispenzieri A; Gonsalves W; Buadi F; Lacy MQ; Hayman SR; Kourelis T; Kapoor P; Go RS; Warsame R; Leung N; Rajkumar SV; Kyle RA; Gertz MA; Kumar SK
Am J Hematol; 2020 May; 95(5):497-502. PubMed ID: 32010993
[TBL] [Abstract][Full Text] [Related]
3. Next generation flow cytometry for MRD detection in patients with AL amyloidosis.
Kastritis E; Kostopoulos IV; Theodorakakou F; Fotiou D; Gavriatopoulou M; Migkou M; Tselegkidi MI; Roussou M; Papathoma A; Eleutherakis-Papaioakovou E; Dialoupi I; Kanellias N; Ntalianis A; Rousakis P; Trougakos IP; Tsitsilonis O; Gakiopoulou C; Terpos E; Dimopoulos MA
Amyloid; 2021 Mar; 28(1):19-23. PubMed ID: 32783569
[TBL] [Abstract][Full Text] [Related]
4. Clinical value of minimal residual disease assessed by multiparameter flow cytometry in amyloid light chain amyloidosis.
Li X; Huang B; Liu J; Chen M; Gu J; Li J
J Cancer Res Clin Oncol; 2022 Apr; 148(4):913-919. PubMed ID: 33966111
[TBL] [Abstract][Full Text] [Related]
5. Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis.
Staron A; Burks EJ; Lee JC; Sarosiek S; Sloan JM; Sanchorawala V
Blood Adv; 2020 Mar; 4(5):880-884. PubMed ID: 32130406
[TBL] [Abstract][Full Text] [Related]
6. Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) for the Treatment of Newly Diagnosed AL Amyloidosis: Impact of Response on Survival Outcomes.
Diaz-Pallares C; Lee H; Luider J; Duggan P; Neri P; Tay J; MacCulloch S; Bahlis NJ; Jimenez-Zepeda VH
Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):394-399. PubMed ID: 32146104
[TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease in systemic light chain amyloidosis: a systematic review and meta-analysis.
Li X; Yu Y; Yu H; Chen M; Zhang X; Wu Y
J Cancer Res Clin Oncol; 2024 Apr; 150(4):193. PubMed ID: 38619663
[TBL] [Abstract][Full Text] [Related]
8. Minimal Residual Disease in Multiple Myeloma: Impact on Response Assessment, Prognosis and Tumor Heterogeneity.
Berger N; Kim-Schulze S; Parekh S
Adv Exp Med Biol; 2018; 1100():141-159. PubMed ID: 30411265
[TBL] [Abstract][Full Text] [Related]
9. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma.
Medina A; Puig N; Flores-Montero J; Jimenez C; Sarasquete ME; Garcia-Alvarez M; Prieto-Conde I; Chillon C; Alcoceba M; Gutierrez NC; Oriol A; Rosinol L; Bladè J; Gironella M; Hernandez MT; Gonzalez-Calle V; Cedena MT; Paiva B; San-Miguel JF; Lahuerta JJ; Mateos MV; Martinez-Lopez J; Orfao A; Gonzalez M; Garcia-Sanz R
Blood Cancer J; 2020 Oct; 10(10):108. PubMed ID: 33127891
[TBL] [Abstract][Full Text] [Related]
10. Measurable residual disease in multiple myeloma and light chain amyloidosis: more than meets the eye.
Vaxman I; Gertz MA
Leuk Lymphoma; 2021 Jul; 62(7):1544-1553. PubMed ID: 33508994
[TBL] [Abstract][Full Text] [Related]
11. Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis.
Dispenzieri A; Arendt B; Dasari S; Kohlhagen M; Kourelis T; Kumar SK; Leung N; Muchtar E; Buadi FK; Warsame R; Kyle RA; Lacy MQ; Dingli D; Kapoor P; Gonsalves WI; Go RS; Hayman SR; Hwa YL; Fonder A; Hobbs M; Jevremovic D; Lust JA; Zeldenrust S; Russell SJ; Rajkumar SV; Gertz MA; Murray D
Blood Cancer J; 2020 Feb; 10(2):20. PubMed ID: 32098948
[TBL] [Abstract][Full Text] [Related]
12. Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis.
Bomsztyk J; Ravichandran S; Giles HV; Wright N; Berlanga O; Khwaja J; Mahmood S; Wisniowski B; Cohen O; Foard D; Gilbertson J; Rauf MU; Starr N; Martinez-Naharro A; Venneri L; Whelan C; Fontana M; Hawkins PN; Gillmore JD; Lachmann H; Harding S; Pratt G; Wechalekar AD
Blood; 2024 Mar; 143(13):1259-1268. PubMed ID: 38194690
[TBL] [Abstract][Full Text] [Related]
13. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.
Flores-Montero J; Sanoja-Flores L; Paiva B; Puig N; García-Sánchez O; Böttcher S; van der Velden VHJ; Pérez-Morán JJ; Vidriales MB; García-Sanz R; Jimenez C; González M; Martínez-López J; Corral-Mateos A; Grigore GE; Fluxá R; Pontes R; Caetano J; Sedek L; Del Cañizo MC; Bladé J; Lahuerta JJ; Aguilar C; Bárez A; García-Mateo A; Labrador J; Leoz P; Aguilera-Sanz C; San-Miguel J; Mateos MV; Durie B; van Dongen JJM; Orfao A
Leukemia; 2017 Oct; 31(10):2094-2103. PubMed ID: 28104919
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis.
Kastritis E; Kostopoulos IV; Terpos E; Paiva B; Fotiou D; Gavriatopoulou M; Kanellias N; Ziogas DC; Roussou M; Migkou M; Eleutherakis-Papaiakovou E; Trougakos IP; Tsitsilonis O; Dimopoulos MA
Blood Cancer J; 2018 May; 8(5):46. PubMed ID: 29795385
[No Abstract] [Full Text] [Related]
15. Clinical Utility of Next-Generation Flow-Based Minimal Residual Disease Assessment in Patients with Multiple Myeloma.
Kim HY; Yoo IY; Lim DJ; Kim HJ; Kim SH; Yoon SE; Kim SJ; Cho D; Kim K
Ann Lab Med; 2022 Sep; 42(5):558-565. PubMed ID: 35470273
[TBL] [Abstract][Full Text] [Related]
16. MRD Assessment in Multiple Myeloma: Progress and Challenges.
Bertamini L; D'Agostino M; Gay F
Curr Hematol Malig Rep; 2021 Apr; 16(2):162-171. PubMed ID: 33950462
[TBL] [Abstract][Full Text] [Related]
17. Long-term CR Multiple Myeloma Patients Show Cured or MGUS-like Minimal Residual Disease Pattern by Next Generation Flow.
Gozzetti A; Pacelli P; Raspadori D; Bestoso E; Tocci D; Sicuranza A; Bocchia M
Rev Recent Clin Trials; 2022; 17(2):92-96. PubMed ID: 35578845
[TBL] [Abstract][Full Text] [Related]
18. [Role of minimal residual disease detection by multiparameter flow cytometry in newly diagnosed multiple myeloma: an analysis of 106 patients].
Deng SH; Xu Y; Sui WW; Wang HJ; Li ZJ; Wang TY; Liu W; Huang WY; Lyu R; Li J; Fu MW; Zou DH; An G; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):376-381. PubMed ID: 29779345
[No Abstract] [Full Text] [Related]
19. [Flow cytometric monitoring of minimal residual diseases in patients with acute leukemia after allogeneic hemapoietic stem cell transplantation].
Gao YQ; Wu T; Wang H; Tong CR; Zhang WJ; Wang JB; Lu Y; Zhao YL; Zhou JR; Sun Y; Zhang YC; Ji SQ; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):84-7. PubMed ID: 22730653
[TBL] [Abstract][Full Text] [Related]
20. Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM).
Fan H; Wang B; Shi L; Pan N; Yan W; Xu J; Gong L; Li L; Liu Y; Du C; Cui J; Zhu G; Deng S; Sui W; Xu Y; Yi S; Hao M; Zou D; Chen X; Qiu L; An G
Clin Cancer Res; 2024 Mar; 30(6):1131-1142. PubMed ID: 38170583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
